Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carolyn F Deacon

Showing results (1-10 of 149) with videos related to

Pageof 15
Sort By:
Diabetes, Obesity & Metabolism|January 25, 2018
A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized controlled trialsCarolyn F Deacon
Expert Opinion on Investigational Drugs|March 21, 2007
Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetesCarolyn F Deacon
Diabetes|August 28, 2012
Is endogenous GLP-1 the only important enhancer of glucose-induced insulin secretion in type 2 diabetes?Carolyn F Deacon
Frontiers in Endocrinology|March 5, 2019
Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 DiabetesCarolyn F Deacon
Current Opinion in Investigational Drugs (London, England : 2000)|May 19, 2005
MK-431 (Merck)Carolyn F Deacon
Peptides|November 11, 2019
Metabolism of GIP and the contribution of GIP to the glucose-lowering properties of DPP-4 inhibitorsCarolyn F Deacon
Nature Reviews. Endocrinology|September 15, 2020
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitusCarolyn F Deacon
Peptides|February 8, 2018
Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetesCarolyn F Deacon
Diabetes, Obesity & Metabolism|October 18, 2007
Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitorsCarolyn F Deacon
Vascular Health and Risk Management|May 14, 2009
Potential of liraglutide in the treatment of patients with type 2 diabetesCarolyn F Deacon
Pageof 15

Showing results (1-10 of 149) with videos related to

Sort By:
Pageof 15
Diabetes, Obesity & Metabolism|January 25, 2018
A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized controlled trialsCarolyn F Deacon
Expert Opinion on Investigational Drugs|March 21, 2007
Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetesCarolyn F Deacon
Diabetes|August 28, 2012
Is endogenous GLP-1 the only important enhancer of glucose-induced insulin secretion in type 2 diabetes?Carolyn F Deacon
Frontiers in Endocrinology|March 5, 2019
Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 DiabetesCarolyn F Deacon
Current Opinion in Investigational Drugs (London, England : 2000)|May 19, 2005
MK-431 (Merck)Carolyn F Deacon
Peptides|November 11, 2019
Metabolism of GIP and the contribution of GIP to the glucose-lowering properties of DPP-4 inhibitorsCarolyn F Deacon
Nature Reviews. Endocrinology|September 15, 2020
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitusCarolyn F Deacon
Peptides|February 8, 2018
Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetesCarolyn F Deacon
Diabetes, Obesity & Metabolism|October 18, 2007
Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitorsCarolyn F Deacon
Vascular Health and Risk Management|May 14, 2009
Potential of liraglutide in the treatment of patients with type 2 diabetesCarolyn F Deacon
Pageof 15